{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:35:10Z","timestamp":1789724110651,"version":"4.0.1"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To assess the possible effects of topiramate and zonisamide use during pregnancy on fetal growth.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>The study population was the singleton liveborns born to women who enrolled in the North American Antiepileptic Drug Pregnancy Registry between 1997 and 2012. Data were collected through telephone interviews at enrollment, 7 months of gestation, and postpartum. The prevalence of small for gestational age at birth among neonates exposed to topiramate and to zonisamide when either was used as monotherapy during pregnancy was compared with that among neonates exposed to lamotrigine monotherapy, a weight-neutral therapy, and the most common antiepileptic drug in the Registry. Relative risks (RRs) and 95% confidence intervals (CIs) were estimated with multivariable log-binomial regression to control for potential confounders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      Data were available for 347 topiramate, 98 zonisamide, and 1,581 lamotrigine-exposed neonates. The mean gestational length was 39 weeks for all comparison groups. Prenatal exposure to topiramate or zonisamide was associated with a mean lower birth weight of 221 and 202 g, respectively, and a mean lesser neonatal length of 1 cm as compared with lamotrigine exposure (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt;.01). The prevalence of small for gestational age was 6.8% for lamotrigine, 17.9% for topiramate (RR 2.4, 95% CI 1.8\u20133.3) and 12.2% for zonisamide (RR 1.6, 0.9\u20132.8). Similar results were found when a group of 457 unexposed neonates was used as the reference.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Topiramate and zonisamide have been shown to reduce weight in adults. Our finding of a decrease in mean birth weight and length among neonates exposed in utero raises concern.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>LEVEL OF EVIDENCE:<\/jats:title>\n                    <jats:p>II<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aog.0000000000000018","type":"journal-article","created":{"date-parts":[[2013,12,9]],"date-time":"2013-12-09T04:18:57Z","timestamp":1386562737000},"page":"21-28","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":75,"title":["Association Between Topiramate and Zonisamide Use During Pregnancy and Low Birth Weight"],"prefix":"10.1097","volume":"123","author":[{"given":"Sonia","family":"Hern\u00e1ndez-D\u00edaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Mittendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Allen","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Yerby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis B.","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20251114","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/oby.2003.78","article-title":"Predictors of weight loss in adults with topiramate-treated epilepsy.","volume":"11","author":"Ben-Menachem","year":"2003","journal-title":"Obes Res"},{"key":"R2-5-20251114","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/oby.2003.102","article-title":". A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity.","volume":"11","author":"Bray","year":"2003","journal-title":"Obes Res"},{"key":"R3-5-20251114","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/sj.ijo.0802783","article-title":"A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. International journal of obesity and related metabolic disorders.","volume":"28","author":"Wilding","year":"2004","journal-title":"Int J Obes Relat Metab Disord"},{"key":"R4-5-20251114","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1345\/aph.1H178","article-title":"Topiramate for binge-eating disorder associated with obesity.","volume":"40","author":"Tata","year":"2006","journal-title":"Ann Pharmacother"},{"key":"R5-5-20251114","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1586\/erc.10.125","article-title":"Phentermine, topiramate and their combination for the treatment of adiposopathy (sick fat) and metabolic disease.","volume":"8","author":"Bays","year":"2010","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"R6-5-20251114","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3945\/ajcn.111.024927","article-title":". Two-year sustained weight loss and metabolic benefits with controlled-release phenterminetopiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.","volume":"95","author":"Garvey","year":"2012","journal-title":"Am J Clin Nutr"},{"key":"R9-5-20251114","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1212\/WNL.0b013e3182574f39","article-title":". Comparative safety of antiepileptic drugs during pregnancy.","volume":"78","author":"Hernandez-Diaz","year":"2012","journal-title":"Neurology"},{"key":"R10-5-20251114","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1212\/01.wnl.0000318293.28278.33","article-title":". Topiramate in pregnancy. Preliminary experience from the UK Epilepsy and Pregnancy Register.","volume":"71","author":"Hunt","year":"2008","journal-title":"Neurology"},{"key":"R11-5-20251114","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0074-7742(08)00019-6","article-title":"Metabolic effects of AEDs: impact on body weight, lipids and glucose metabolism.","volume":"83","author":"Sheth","year":"2008","journal-title":"Int Rev Neurobiol"},{"key":"R13-5-20251114","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1001\/jama.289.14.1820","article-title":"Zonisamide for weight loss in obese adults: a randomized controlled trial.","volume":"289","author":"Gadde","year":"2003","journal-title":"JAMA"},{"key":"R14-5-20251114","doi-asserted-by":"crossref","first-page":"50","DOI":"10.4088\/JCP.v65n0108","article-title":"Zonisamide in the treatment of binge-eating disorder: an open-label, prospective trial.","volume":"65","author":"McElroy","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"R15-5-20251114","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/2013.jamainternmed.99","article-title":"Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial.","volume":"172","author":"Gadde","year":"2012","journal-title":"Arch Intern Med"},{"key":"R17-5-20251114","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.reprotox.2008.03.001","article-title":"The outcome of pregnancy following topiramate treatment: a study on 52 pregnancies.","volume":"25","author":"Ornoy","year":"2008","journal-title":"Reprod Toxicol"},{"key":"R18-5-20251114","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1001\/archneur.61.5.673","article-title":"The antiepileptic drug pregnancy registry: a six year experience.","volume":"61","author":"Holmes","year":"2004","journal-title":"Arch Neurol"},{"key":"R19-5-20251114","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1212\/01.WNL.0000154516.43630.C5","article-title":"Increased rate of major malformations in offspring exposed to valproate during pregnancy.","volume":"64","author":"Wyszynski","year":"2005","journal-title":"Neurology"},{"key":"R20-5-20251114","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1212\/01.wnl.0000304343.45104.d6","article-title":"Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy.","volume":"70","author":"Holmes","year":"2008","journal-title":"Neurology"},{"key":"R21-5-20251114","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2431-3-6","article-title":"A nearly continuous measure of birth weight for gestational age using a United States national reference.","volume":"3","author":"Oken","year":"2003","journal-title":"BMC Pediatr"},{"key":"R22-5-20251114","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0899-9007(00)00452-4","article-title":"Influence of topiramate in the regulation of energy balance.","volume":"16","author":"Richard","year":"2000","journal-title":"Nutrition"},{"key":"R23-5-20251114","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0140-6736(13)60311-6","article-title":"Effect of fetal and child health on kidney development and long-term risk of hypertension and kidney disease.","volume":"382","author":"Luyckx","year":"2013","journal-title":"Lancet"},{"key":"R24-5-20251114","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.annepidem.2010.11.012","article-title":"Prepregnancy body mass index, smoking during pregnancy, and infant birth weight.","volume":"21","author":"La Merrill","year":"2011","journal-title":"Ann Epidemiol"},{"key":"R25-5-20251114","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1210\/er.2006-0039","article-title":"Small for gestational age: short stature and beyond.","volume":"28","author":"Saenger","year":"2007","journal-title":"Endocr Rev"},{"key":"R26-5-20251114","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1055\/s-0031-1284224","article-title":"The relationship between maternal body mass index and tobacco use on small-for-gestational-age infants.","volume":"29","author":"Goetzinger","year":"2012","journal-title":"Am J Perinatol"},{"key":"R27-5-20251114","first-page":"S1","article-title":"Topiramate for weight loss.","volume":"20","author":"Dugan","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006250-201401000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T22:00:31Z","timestamp":1763157631000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006250-201401000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000000018","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}